We investigated the CD28 expression on 10 MM cell lines and plasma cells from 100 NDMM and 40 RRMM patients, as well as the potency of the trispecific antibody SAR442257 (anti-CD38/CD3xCD28) on primary samples from RRMM patients. This evidence concerns the gene CD28 and Miyoshi myopathy.